Literature DB >> 26711784

MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus.

Renata Hezova1,2, Alena Kovarikova1, Josef Srovnal3, Milada Zemanova4, Tomas Harustiak5, Jiri Ehrmann3, Marian Hajduch3, Milana Sachlova2, Marek Svoboda2, Ondrej Slaby6,7,8.   

Abstract

Esophageal cancer is a malignant disease with poor prognosis, increasing incidence, and ineffective treatment options. MicroRNAs are post-transcriptional regulators of gene expression involved in many biological processes including carcinogenesis. We determined miR-205 expression levels in tumor/non-tumor tissues of 45 esophageal cancer patients using qPCR and found that decreased level of miR-205 in tumor tissue correlates with poor overall survival in esophageal adenocarcinoma patients. Further, we observed significantly higher levels of miR-205 in tumor tissue of esophageal squamous cell carcinoma. Ectopic overexpression of miR-205 in adenocarcinoma cell line SK-GT-4 led to decreased cell proliferation, cell cycle arrest in G1, and decreased migration ability. Conversely, in squamous cell line KYSE-150, same effects like inhibition of proliferation, migration, and colony-forming potential and cell cycle arrest in G2 were observed after silencing of miR-205. We performed global gene expression profiling and revealed that suppressive functioning of miR-205 in adenocarcinoma could be realized through regulation of epithelial-mesenchymal transition (EMT), whereas oncogenic in squamous cell carcinoma by regulation of metalloproteinase 10. Our results suggest that miR-205 could serve as biomarker in esophageal cancer and acts as a tumor suppressor in esophageal adenocarcinoma and oncogene in esophageal squamous cell carcinoma.

Entities:  

Keywords:  Esophageal adenocarcinoma; Esophageal squamous cell carcinoma; Oncogene; Tumor suppressor; miR-205

Mesh:

Substances:

Year:  2015        PMID: 26711784     DOI: 10.1007/s13277-015-4656-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  47 in total

1.  Meta-analysis of microRNA expression in lung cancer.

Authors:  Urmo Võsa; Tõnu Vooder; Raivo Kolde; Jaak Vilo; Andres Metspalu; Tarmo Annilo
Journal:  Int J Cancer       Date:  2012-12-27       Impact factor: 7.396

Review 2.  Upper gastrointestinal cancer predisposition syndromes.

Authors:  Manish A Shah; Robert C Kurtz
Journal:  Hematol Oncol Clin North Am       Date:  2010-10       Impact factor: 3.722

3.  miRNA-205 is a candidate tumor suppressor that targets ZEB2 in renal cell carcinoma.

Authors:  Zhi Chen; Zheng-Yan Tang; Yao He; Long-Fei Liu; Dong-Jie Li; Xiang Chen
Journal:  Oncol Res Treat       Date:  2014-10-17       Impact factor: 2.825

4.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

5.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Authors:  David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

6.  MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis.

Authors:  Chi-Hong Chao; Chao-Ching Chang; Meng-Ju Wu; How-Wen Ko; Da Wang; Mien-Chie Hung; Jer-Yen Yang; Chun-Ju Chang
Journal:  J Clin Invest       Date:  2014-06-09       Impact factor: 14.808

7.  miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon.

Authors:  Paolo Gandellini; Marco Folini; Nicole Longoni; Marzia Pennati; Mara Binda; Maurizio Colecchia; Roberto Salvioni; Rosanna Supino; Roberta Moretti; Patrizia Limonta; Riccardo Valdagni; Maria Grazia Daidone; Nadia Zaffaroni
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

8.  Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up.

Authors:  Athina Markou; George M Yousef; Efstathios Stathopoulos; Vassilis Georgoulias; Evi Lianidou
Journal:  Clin Chem       Date:  2013-10-16       Impact factor: 8.327

9.  Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors.

Authors:  Y Xu; T Brenn; E R S Brown; V Doherty; D W Melton
Journal:  Br J Cancer       Date:  2012-01-05       Impact factor: 7.640

10.  ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression.

Authors:  Kai Li; Ling Yao; Li Chen; Zhi-Gang Cao; San-Jian Yu; Xia-Ying Kuang; Xin Hu; Zhi-Ming Shao
Journal:  Onco Targets Ther       Date:  2014-06-18       Impact factor: 4.147

View more
  16 in total

1.  Expression of miRNA in 5-FU resistant esophageal cancer.

Authors:  Prasit Mahawongkajit; Prakitpunthu Tomtitchong
Journal:  Mol Clin Oncol       Date:  2020-06-11

2.  Long non-coding RNA ELF3-antisense RNA 1 promotes osteosarcoma cell proliferation by upregulating Kruppel-like factor 12 potentially via methylation of the microRNA-205 gene.

Authors:  Jianmin Yuan; Jianhui Kang; Min Yang
Journal:  Oncol Lett       Date:  2020-01-16       Impact factor: 2.967

3.  MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway.

Authors:  Ping Shao; Wei-Kun Qu; Cheng-Ye Wang; Yu Tian; Ming-Liang Ye; De-Guang Sun; Ji-Dong Sui; Li-Ming Wang; Rong Fan; Zhen-Ming Gao
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

4.  Identification and in vitro validation of diagnostic and prognostic biomarkers for lung squamous cell carcinoma.

Authors:  Xiaopeng Zhao; Chong Yuan; Xu He; Miao Wang; Haoran Zhang; Jingge Cheng; Hongyan Wang
Journal:  J Thorac Dis       Date:  2022-04       Impact factor: 2.895

5.  Prognostic Value of MicroRNAs in Esophageal Carcinoma: A Meta-Analysis.

Authors:  Song Gao; Zhi-Ying Zhao; Zhen-Yong Zhang; Yue Zhang; Rong Wu
Journal:  Clin Transl Gastroenterol       Date:  2018-11-13       Impact factor: 4.488

6.  miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCε and ZEB1 inhibition.

Authors:  Rihan El Bezawy; Stella Tinelli; Monica Tortoreto; Valentina Doldi; Valentina Zuco; Marco Folini; Claudio Stucchi; Tiziana Rancati; Riccardo Valdagni; Paolo Gandellini; Nadia Zaffaroni
Journal:  J Exp Clin Cancer Res       Date:  2019-02-04

7.  Somatic Mutations in miRNA Genes in Lung Cancer-Potential Functional Consequences of Non-Coding Sequence Variants.

Authors:  Paulina Galka-Marciniak; Martyna Olga Urbanek-Trzeciak; Paulina Maria Nawrocka; Agata Dutkiewicz; Maciej Giefing; Marzena Anna Lewandowska; Piotr Kozlowski
Journal:  Cancers (Basel)       Date:  2019-06-08       Impact factor: 6.639

8.  Evaluation of MicroRNA-99a and MicroRNA-205 Expression Levels in Bladder Cancer.

Authors:  Sajjad Mohammad Ganji; Massoud Saidijam; Razieh Amini; Seyed Habibollah Mousavi-Bahar; Nooshin Shabab; Saman Seyedabadi; Ali Mahdavinezhad
Journal:  Int J Mol Cell Med       Date:  2017-07-08

9.  Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.

Authors:  Silvia Di Agostino; Fabio Valenti; Andrea Sacconi; Giulia Fontemaggi; Matteo Pallocca; Claudio Pulito; Federica Ganci; Paola Muti; Sabrina Strano; Giovanni Blandino
Journal:  Theranostics       Date:  2018-02-12       Impact factor: 11.556

10.  Identification of microRNAs as novel biomarkers for esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas (TCGA) and bioinformatics.

Authors:  Cheng-Yun Li; Wen-Wen Zhang; Ji-Lian Xiang; Xing-Hua Wang; Jin Li; Jun-Ling Wang
Journal:  Chin Med J (Engl)       Date:  2019-09-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.